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Abstract

Hypoxia and angiogenesis can significantly influence the efficacy of cancer therapy and the behavior of surviving
tumor cells. There is a growing demand for technologies to measure tumor hypoxia and angiogenesis
temporally in vivo to enable advances in drug development and optimization. This paper reports the use of
frequency-domain photon migration with a side-firing probe to quantify tumor oxygenation and hemoglobin
concentrations in nude rats bearing human head/neck tumors administered with carbogen gas, cycling hypoxic
gas or just room air. Significant increase (with carbogen gas breathing) or decrease (with hypoxic gas breathing)
in tumor oxygenation was observed. The trend in tumor oxygenation during forced cycling hypoxia (CH)
followed that of the blood oxygenation measured with a pulse oximeter. Natural CH was also observed in rats
under room air. The studies demonstrated the potential of the technology for longitudinal monitoring of tumor
CH during tumor growth or in response to therapy.
A flat side-firing fiber optic probe based on frequency-domain photon migration can be easily and reliably
attached to a tumor surface for longitudinal monitoring of tumor cycling hypoxia and angiogenesis.
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1. Introduction
Hypoxia and angiogenesis are two important characteristics of growing human tumors. Tumor hypoxia or low
oxygen status is a spatially and temporally heterogeneous phenomenon, and is influenced by both the oxygen

consumption rate of tumor cells and the oxygen supply from blood vessels [1, 2]. Proliferating cells have an
oxygen consumption rate that is 3–5 times greater than that of inactive cells [3–5]. Limited oxygen supply to the
tumor can be caused by low vascular density, abnormal vascular orientation, or a paucity of arterial supply
vessels [2]. Hypoxia generates a stress response which signals the tumor cells to stimulate blood vessel growth
or angiogenesis to provide rapidly proliferating tumor cells with an adequate supply of oxygen and metabolites
[2, 6, 7]. The blood vessels in tumors grow much more rapidly than the normal blood vessels, but they are
abnormal and leaky, further perpetuating tumor hypoxia.
In a fast growing tumor oxygen diffuses a distance of 100–150 μm from blood vessels which divides a tumor into
two different hypoxic regions [8, 9]. Tumor cells beyond the diffusion distance become chronically hypoxic due
to poor oxygen supply. Within the diffusion limit, however, tumor oxygenation often shows a temporal
fluctuation with clear patterns of periodicity across many tumor types, a phenomenon known as cycling hypoxia
(CH) or intermittent (or acute) hypoxia [2, 7–12]. CH has been found in both animal and human solid tumors.
Depending on the architectural complexity and maturation level of the tumor vascular network, the periodicity
of tumor CH can range between tens of seconds to hours, or even days and varies across tumors and also within
the same tumor [2, 11, 12]. The higher frequency (tens of seconds – hours) is associated with changes in
perfusion, red blood cell flux, and occasionally vascular occlusion, while the lower frequency (days) is believed to
be caused by changes in vascular network structures as a consequence of vascular reformation and angiogenesis
[8, 12].
Tumor angiogenesis and hypoxia, particularly CH, can significantly influence the efficacy of radiotherapy and
chemotherapy as well as the behavior of surviving cancer cells. Angiogenesis and hypoxia are inextricably linked
to the propensity of a tumor to grow. It is well known that hypoxia leads to neovascularization in order to satisfy
the increased need of proliferating tumor cells, enhanced tumor metastasis, and resistance to radiation and
chemotherapy by increasing genetic instability and selecting for cells with a diminished apoptotic potential
[8, 13, 14]. It has been recently demonstrated that CH also increases tumor angiogenesis by increasing hypoxiainducible factor 1α (HIF-1α stabilization and HIF-1 activation [7, 15] and confers tumor cells and tumor vascular
endothelial cells with enhanced pro-survival pathways, making tumors less responsive to radiation and
chemotherapy. However the dynamic interplay between hypoxia and angiogenesis and how best to leverage
these targets for cancer therapy is still the subject of numerous investigations. Hypoxia-directed intensitymodulated radiotherapy and anti-angiogenic therapy in combination with cytotoxic chemotherapy are examples
of current approaches that are being explored to target tumor hypoxia and/or angiogenesis in various tumor
entities [16, 17]. There is growing demand for technologies to measure tumor hypoxia and angiogenesis
temporally in vivo to enable advances in drug screening, development and optimization.
Pre-clinical tumor models are important test beds in the development of drug therapies because they allow for
rapid and systematic evaluation of different combinations of therapy and doses as well as the sequence in which
they are administered in a relatively fast and cost-effective manner before proceeding to expensive, timeconsuming clinical trials. However, the insights gained from pre-clinical model studies are only as effective as the
tools used to measure the relevant endpoints. Sophisticated imaging techniques such as electron paramagnetic
resonance imaging (EPRI), positron-emission tomography (PET), magnetic resonance imaging (MRI),
fluorescence redox imaging and photoacoustic imaging can be used to image tumor hypoxia and angiogenesis
with a spatial resolution from several millimeters down to a few micrometers [12, 18]. However, these tools are
not amenable to frequent use and thus at best can only report on events at selected time points over the course
of cancer therapy. Moreover, multiple types of sophisticated imaging modalities maybe needed to fully capture
events related to tumor hypoxia and angiogenesis. These tools could miss opportunistic time points and/or the
interaction between key bio-markers that report on the effect of a particular drug. Needle-based oxygen
electrodes and fluorescence oxygen sensors have also been widely used in the past, but these techniques are

invasive, sample a very small volume, and have short lifetime. Immunohistochemistry of tissue biopsies suffers
from similar drawbacks, in addition to the fact that biopsies are invasive and sample only very small volumes of
tumor, which may not represent the overall tumor behavior.
Frequency-domain photon migration (FDPM) or diffuse optical spectroscopy (DOS) is a noninvasive technology
that can provide quantitative information about tumor physiology, including tissue hemoglobin content and
oxygenation status [19–27]. We previously reported a three-wavelength FDPM instrument and a side-firing fiber
optic probe as an adjunct tool for breast cancer detection during image guided core-needle biopsy [28]. We
have recently upgraded the instrument and redesigned a completely flat side-firing probe. The new system can
quantitatively measure bulk tissue absorption and scattering spectra between 650–1000 nm with a penetration
depth between 5–15 mm within human tissue. The concentrations of deoxyhemoglobin (Hb) and
oxyhemoglobin (HbO2 ) can be determined from the absorption spectra. The side-firing probe can be easily and
reliably attached to a flat skin surface, making it an ideal tool for continuous monitoring of tumor physiology in
preclinical tumor models. In this paper, we report the use of the side-firing probe in a preclinical model for
longitudinal monitoring of head & neck (FaDu) tumor physiology in response to high or low oxygen levels or just
room air. The tissue oxygen saturation measured via side-firing probe accurately tracked the varying
oxygenation status of the tumor and was concordant with arterial blood oxygen saturation measured with a
mouse pulse oximeter. Natural CH with patterns and frequency range similar to those reported in literature was
also recorded in some rats under room air. To the best of our knowledge, this is the first time natural tumor CH
was observed in animal models using a noninvasive optical technique.

2. Materials and methods
2.1 Instrument
In this study, the FDPM instrument was upgraded to include 6 laser wavelengths (654, 683, 779, 805, 847, and
905 nm) so that more absorbers, such as water and fat, can be accounted for. Figure 1(a) shows a photograph of
the 6-wavelength FDPM instrument. The needle-shaped side-firing fiber optic probe used in the previous breast
biopsy study was modified to have a completely flat surface by gluing all fiber tips into a V-groove on a thin
Delrin plate so that it could be easily attached on to the surface of a rat tumor, shown in Figures 1(b) and (c).
The probe has two side-firing source fibers (200/220/240 μm, NA = 0.22) and a single side-firing detection fiber
(600/660/710 μm, NA = 0.22), providing two source-detector separations (SDS) of 5 and 10 mm, respectively.
The fiber tips were polished to a 45° angle and coated with a mirror to create a light path perpendicular to the
fiber. The two source-detector separations were used to eliminate instrumentation artifacts due to modulationdependence of the light sources and instrument response [29, 30] and skin effects. The fibers were relayed to
the instrument via a 2.5 mm fiber optic cable with FC connectors. The FDPM instrument launches intensitymodulated continuous wave lasers into the tissue and collects the amplitude-attenuated and phase-shifted
diffuse reflectance from the tissue at the same frequency of the incident light. The optical switch outputs each
of the six wavelengths to one of two source fibers sequentially and the modulation frequency was scanned from
50 to 250 MHz at a 1 MHz interval at each wavelength. A custom LabVIEW program integrated with Matlab
scripts was used for instrument control, data acquisition and data analysis. The measured tissue optical
properties as well as composition parameters were displayed in real-time.

Figure 1 FDPM instrument and side-firing probe: (a) photograph of the instrument; (b) a schematic of the sidefiring fiber optic probe; and (c) a cartoon of the coupling between the side-firing probe and rat tumor.

2.2 Phantom study
Tissue-simulating liquid phantoms were used to evaluate the performance of the system and for instrument
calibration. 15 phantoms with absorption (𝜇𝜇𝑎𝑎 ) and reduced scattering coefficients (𝜇𝜇𝑠𝑠′ ) representative of rat
tumors at the six wavelengths [21, 31] were created by fixing the number of scatterers (or volume of 20% stock
Intralipid solution) at three levels (low, medium and high) and titrating stock India ink solution (absorber) to five
levels. The extinction coefficient of the stock ink solution was measured using a spectrophotometer (Cary 300,
Varian, Inc.) and the expected 𝜇𝜇𝑠𝑠′ of the stock Intralipid was determined by using the method described in Ref.
[32]. Table 1 summarizes the expected phantom 𝜇𝜇𝑎𝑎 and 𝜇𝜇𝑠𝑠′ averaged over all the six wavelengths.
Table 1 Expected phantom 𝜇𝜇𝑎𝑎 and 𝜇𝜇𝑠𝑠′ averaged over all six wavelengths.
Phantom # 𝝁𝝁𝜶𝜶 (cm−1) 𝜇𝜇𝑠𝑠′ (cm−1) Phantom # 𝝁𝝁𝜶𝜶 (cm−1) 𝜇𝜇𝑠𝑠′ (cm−1)
1
0.108
10.63
9
0.305
14.01
2
0.162
10.60
10
0.376
13.99
3
0.234
10.55
11
0.108
17.71
4
0.305
10.51
12
0.162
17.66
5
0.376
10.47
13
0.234
17.59
6
0.108
14.17
14
0.305
17.52
7
0.162
14.12
15
0.376
17.45
8
0.234
14.07

2.3 Animal tumor models

A human head & neck tumor model (FaDu) in athymic nude rats (Charles River, Durham, North Carolina) was
used for the study. A total number of 26 rats (200–240 g) were used in the experiments and the animals were
divided into three groups. 8 tumor-bearing rats were assigned to Group 1 and exposed to carbogen gas (95%
O2 and 5% CO2 ) for the duration of the experiment. Group 2 had 10 tumor-bearing and 4 control (tumor-free)
rats for the forced CH experiment. Finally, 4 rats were assigned to Group 3 and used to study natural CH. The
study was approved by the Duke Institutional Animal Care and Use Committee.
To grow the FaDu tumor, about 5 million FaDu cells were injected into the left flank of the rat. The tumors were
allowed to grow to a size of ~2.0 cm in diameter (in 3–4 weeks). In each experiment, the side-firing probe was
placed on the surface of the tumor or flank muscles (controls) during the study, as shown in Figure 2. The probe
has an estimated sensing depth of 5–15 mm. A piece of medical dark tape was used to hold the probe in place

and prevent the room light from saturating the avalanche photodiode (APD) detector. At the end of the
experiment the rat was sacrificed using an overdose of Pentobarbital.

Figure 2 Photograph of a rat with a side-firing probe attached.

2.3.1 Carbogen inhalation experiment

In the first experiment, 8 nude rats (Group 1) bearing a FaDu tumor underwent carbogen inhalation. The rats
were subject to measurements when the tumors reached a size of approximately 2 cm × 2 cm. The animals were
anesthetized with Pentobarbital at a dose of 50 mg/kg. The experimental procedure is depicted in Figure 3(a).
The rats were first exposed to room air for 10 minutes as a baseline (or normoxia), followed by carbogen gas
(hyperoxia) through a nosecone for 15 minutes and 20 minutes of room air for recovery. Optical measurements
were taken at one-minute intervals resulting in a total of 45 data points for each animal.

Figure 3 Experimental procedures for (a) carbogen (95% O2 and 5% CO2 ) inhalation and (b) for cycling hypoxic
gas breathing (30% O2 was used for normoxia instead of 21%).

2.3.2 Forced CH

In the second experiment, 10 tumor bearing rats and 4 normal controls (Group 2) were provided with cycling
hypoxic gas following the procedure outlined in Figure 3(b). The experiments were conducted when tumors
were approximately 2 cm × 2 cm. The animals were anesthetized with Pentobarbital at a dose of 50 mg/kg. The
rats were first provided normoxic gas (30% O2 and 70 N2 ) for 10 minutes as a baseline, followed by hypoxic gas
(mixture of 12% O2 and 88% N2 ) for 10 minutes. The procedure was repeated for two cycles. Finally, the rats
were provided with normoxic gas again for another 10 minutes to follow recovery. Because Pentobarbital
injection was used for anesthesia, the oxygen concentration for the normoxia phases was slightly raised from
the natural level of 21% to 30% to better simulate a natural normoxic condition. An optical measurement was
taken every minute, resulting in a total of 50 data points. A mouse pulse oximeter (Mouse Ox, Starr Life Science
Corp., Allison Park, PA) was also clamped on to the left foot of the rat and the arterial blood oxygen saturation
was collected every 5 seconds as a reference as well as for rat condition monitoring.

2.3.3 Natural CH

To evaluate the capability of the side-firing probe in capturing natural CH, a much weaker signal comparing to
the forced CH, 4 nude rats (Group 3) bearing a FaDu tumor were used to investigate the capability of the sidefiring probe in quantifying and continuous monitoring natural tumor CH. The animals were anesthetized with a
mixture of vaporized Isofluorane and fresh air under a fume hood during the experiment. The first 2 animals
(Group 3A) were measured on two different days: Day 1 – before tumor cells were injected and Day 2 – when
the tumor size reached approximately 2 cm in diameter (3–4 weeks later). The 2 remaining rats (Group 3B) were
measured on three different days: Day 1 – before tumor cells were injected, Day 2 – when the tumor size
reached approximately 0.5 cm in diameter, and Day 3 – when the tumor size reached approximately 1.5 cm in
diameter. On each day optical measurements were taken from each animal at one-minute intervals for about
120–150 minutes. The purpose was to study the relationship between CH and tumor size.

2.4 Data analysis
In frequency-domain photon migration, the AC component of the amplitude AC (r, λ, ω) and phase-shift Φ(r, λ,
ω) of the diffuse reflectance of the photon density wave collected by the detection fiber from the surface of a
semi-infinite medium at SDS = r can be expressed by the following equations that were modified from Eqs. (8)–
(13) in Ref. [20]:

AC (𝑟𝑟, 𝜆𝜆, 𝜔𝜔) = (𝐴𝐴0 /4𝜋𝜋 𝐷𝐷) (REAL2 + IMAG2 )1/2

(1)

𝜙𝜙(𝑟𝑟, 𝜆𝜆, 𝜔𝜔) = 𝜙𝜙0 + 𝑘𝑘imag (𝜔𝜔) 𝑟𝑟0 − arctan (IMAG/REAL)

(2)
where,

(3)

(4)

REAL = exp[ − 𝑘𝑘real(𝜔𝜔) 𝑟𝑟0 ]/𝑟𝑟0 − cos�𝑘𝑘imag (𝜔𝜔) (𝑟𝑟0𝑏𝑏 − 𝑟𝑟0 )� × exp[ − 𝑘𝑘real (𝜔𝜔)𝑟𝑟0𝑏𝑏 ]/𝑟𝑟0𝑏𝑏

IMAG = sin�𝑘𝑘imag (𝜔𝜔) (𝑟𝑟0𝑏𝑏 − 𝑟𝑟0 )� exp[ − 𝑘𝑘real (𝜔𝜔)𝑟𝑟0𝑏𝑏 ]/𝑟𝑟0𝑏𝑏
𝑟𝑟0 = [(1/𝜇𝜇𝑠𝑠′ )2 + 𝑟𝑟 2 ]1/2

(5)

(6)

(7)

(8)

𝑟𝑟0𝑏𝑏 = {[4(1 + 𝑅𝑅eff )/3𝜇𝜇𝑠𝑠′ (1 − 𝑅𝑅eff )]2 + 𝑟𝑟 2 }1/2
𝑘𝑘real = �3𝜇𝜇𝑎𝑎 𝜇𝜇𝑠𝑠′ /2{[1 + (𝜔𝜔/𝜈𝜈𝜇𝜇𝑎𝑎 )2 ]1⁄2 + 1}1⁄2
𝑘𝑘real = �3𝜇𝜇𝑎𝑎 𝜇𝜇𝑠𝑠′ /2{[1 + (𝜔𝜔/𝜈𝜈𝜇𝜇𝑎𝑎 )2 ]1⁄2 + 1}1⁄2
𝐷𝐷 = 1/3(𝜇𝜇𝑎𝑎 + 𝜇𝜇𝑠𝑠′ )

(9)

and 𝐴𝐴0 is the net amplitude response of the instrument, 𝜙𝜙0 is the initial phase shift due to the cables and
electronics, 𝑅𝑅eff is an effective reflection coefficient (𝑅𝑅eff = 0.431 for air-water and 0.493 for air-tissue
interfaces), 𝜈𝜈 is the velocity of light in the medium, and 𝜔𝜔 = 2𝜋𝜋𝑓𝑓 is the angular modulation frequency,
where 𝑓𝑓 is the modulation radio frequency. The major modification is that an initial phase shift 𝜙𝜙0 due to cables
and electronics compared with that of the local reference RF signal is added to the total phase.
Assuming that the two source fibers had identical signal attenuation and initial phase delay, the relative
amplitude attenuation (ΔAC (𝜆𝜆, 𝜔𝜔)) was obtained by dividing the amplitude of the long SDS (𝑟𝑟2 ) by that of the
short SDS (𝑟𝑟1 ) and the relative phase-shift (Δ𝛷𝛷(𝜆𝜆, 𝜔𝜔)) was calculated as the difference between the phases of
the two SDSs:

(10)

ΔAC(𝜆𝜆, 𝜔𝜔) = AC(𝑟𝑟2 , 𝜆𝜆, 𝜔𝜔)/AC(𝑟𝑟1 , 𝜆𝜆, 𝜔𝜔)
= {[REAL(𝑟𝑟2 , 𝜆𝜆, 𝜔𝜔) + IMAG(𝑟𝑟2 , 𝜆𝜆, 𝜔𝜔)2 ]/[REAL(𝑟𝑟1 , 𝜆𝜆, 𝜔𝜔)2 + IMAG(𝑟𝑟1 , 𝜆𝜆, 𝜔𝜔)2 ]}1⁄2

(11)

Δ𝜙𝜙(𝜆𝜆, 𝜔𝜔) = 𝜙𝜙(𝑟𝑟2 , 𝜆𝜆, 𝜔𝜔) − 𝜙𝜙(𝑟𝑟1 , 𝜆𝜆, 𝜔𝜔)
= 𝑘𝑘imag (𝜆𝜆, 𝜔𝜔)[𝑟𝑟0 (𝑟𝑟2 , 𝜆𝜆) − 𝑟𝑟0 (𝑟𝑟1 , 𝜆𝜆)] − arctan[IMAG(𝑟𝑟2 , 𝜆𝜆, 𝜔𝜔)⁄REAL(𝑟𝑟2 , 𝜆𝜆, 𝜔𝜔)] +
𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎[IMAG(𝑟𝑟1 , 𝜆𝜆, 𝜔𝜔)/REAL(𝑟𝑟1 , 𝜆𝜆, 𝜔𝜔)]

2

By using two source-detector separations, the source term 𝐴𝐴0 and initial phase shift 𝜙𝜙0 can be removed, which
makes the system insensitive to the absolute instrument throughput and phase shift as well as fluctuations. The
relative attenuation and the phase-shift of these photon density waves in a semi-finite medium are determined
by three wave characteristics, the modulation frequency 𝑓𝑓, the source-detector separations (𝑟𝑟1 and 𝑟𝑟2 ), and the
medium characteristics (𝜇𝜇𝑎𝑎 and 𝜇𝜇𝑠𝑠′ ).

The tissue or phantom optical properties 𝜇𝜇𝑠𝑠′ (𝜆𝜆) at each wavelength 𝜆𝜆𝜆𝜆 were independently extracted by fitting
the measured relative diffuse reflectance data to the theoretical model based on Eqs. (3)–(11). The data analysis
algorithm was implemented by a MATLAB (MathWorks, Inc., Natick, MA) script node in LabVIEW (National
Instruments Corp., Austin, TX). A Levenberg-Marquardt nonlinear least square minimization algorithm was
adapted to simultaneously fit the relative amplitude ΔAC (𝜆𝜆, 𝜔𝜔) with a weight 𝛼𝛼 and phase-shift Δ𝛷𝛷 (𝜆𝜆, 𝜔𝜔) with
a weight (1 − 𝛼𝛼). An optimal 𝛼𝛼 = 0.8 has been used for both the phantom and animal studies described in

this paper. Various initial guesses of {𝜇𝜇𝑎𝑎0 (𝜆𝜆), 𝜇𝜇𝑠𝑠′ (𝜆𝜆), 𝛼𝛼0 } were used to guarantee that the chi-squared value
(goodness-of-fit metric) was at the global minimum.

To account for the difference between the theoretical model and experimental data and difference in the
attenuation and optical path length of the two source fibers, the relative amplitude and phase shift obtained
from one or multiple reference phantoms were fit to the diffusion model to generate three correction factor
matrices: an amplitude multiplication factor 𝑋𝑋(𝜆𝜆𝑖𝑖 ), an amplitude offset factor 𝑌𝑌(𝜆𝜆𝑖𝑖 ) and a frequency-dependent
phase offset factor 𝑍𝑍(𝜆𝜆𝑖𝑖 , 𝑓𝑓) as given by:

(12)

(13)

ΔACtheoretical (𝜆𝜆𝑖𝑖 ) = 𝑋𝑋(𝜆𝜆𝑖𝑖 ) · ΔACref_phantom (𝜆𝜆𝑎𝑎 ) + 𝑌𝑌(𝜆𝜆𝑖𝑖 )
Δ𝜙𝜙theoretical (𝜆𝜆𝑖𝑖 , 𝑓𝑓) = Δ𝜙𝜙ref_phantom (𝜆𝜆𝑖𝑖 , 𝑓𝑓) + 𝑍𝑍(𝜆𝜆𝑖𝑖 , 𝑓𝑓)

The correction factors were then applied to the relative amplitude and phase shift measured from the animals
before the nonlinear least square fitting.
Next, tissue physiological parameters, including HbO2 concentration CHbO2 , Hb concentration CHb , total
hemoglobin concentration (THb) and tissue oxygenation (SO2 ) were calculated from the absorption coefficients
that were extracted from the tissue spectra, using the Eqs. (14)–(16):

(14)

𝜇𝜇𝑎𝑎 (𝜆𝜆𝑖𝑖 ) = 2.303 · [𝜀𝜀(HbO2,𝜆𝜆𝑖𝑖 ) CHbO2 + 𝜀𝜀(Hb,𝜆𝜆𝑖𝑖 ) CHb ]

(15)

(16)

THb = CHbO2 + CHb
SO2 = CHbO2 /THb

where 𝜀𝜀(HbO2 ,𝜆𝜆𝑖𝑖 ) and 𝜀𝜀(Hb,𝜆𝜆𝑖𝑖 ) are the extinction coefficients of HbO2 and Hb, respectively.

In both the carbogen inhalation and forced CH experiments, one-way repeated measures ANOVA was employed
to examine if there is statistically significant difference between the tissue physiological parameters (SO2 and
THb) under different oxygen supply levels.

3. Results
3.1 Phantom study
The diffuse reflectance spectra measured from 15 Intralipid phantoms were analyzed using Eqs. (3)–(13) at each
wavelength. Figure 4(a) shows the raw, calibrated and expected (modeled) ΔAC and ΔΦ between 50–250 MHz at
654 nm for phantoms #1, 8 and 15 with low, medium and high (𝜇𝜇𝑎𝑎 , 𝜇𝜇𝑠𝑠′ ), respectively. Using a modulation
frequency depend calibration factor 𝑍𝑍(𝜆𝜆𝑖𝑖 , 𝑓𝑓) significantly improved the fits between the experimental and
modeled phase spectra Δ𝛷𝛷(𝜆𝜆, 𝜔𝜔) compared with calibration with a frequency-independent phase offset
factor 𝑍𝑍(𝜆𝜆𝑖𝑖 ) that was used in the previous biopsy study [28]. The calibrated relative amplitude and phase shift
were used to extract the phantom 𝜇𝜇𝑎𝑎 and 𝜇𝜇𝑠𝑠′ at all wavelengths. Figure 4(b) is a scattered plot of the extracted

vs. expected phantom 𝜇𝜇𝑎𝑎 and 𝜇𝜇𝑠𝑠′ at all the 6 wavelengths for all 15 phantoms. The errors
for 𝜇𝜇𝑎𝑎 and 𝜇𝜇𝑠𝑠′ extraction are 9.4 ± 2.8% and 3.4 ± 1.4% with frequency dependent phase calibration, and 14.6 ±
7.7% and 7.3 ± 1.4% with frequency independent phase calibration, respectively.

Figure 4 Phantom results: (a) Raw and calibrated relative amplitude and phase spectra (in frequency domain) for
phantoms #1, 8 and 15. (b) Extracted v.s. expected 𝜇𝜇𝑎𝑎 and 𝜇𝜇𝑠𝑠′ at all wavelengths for all phantoms. The errors
for 𝜇𝜇𝑎𝑎 and 𝜇𝜇𝑠𝑠′ extraction are 9.4 ± 2.8% and 3.4 ± 1.4% with frequency dependent phase calibration and 14.6 ±
7.7% and 7.3 ± 1.4% with frequency independent phase calibration, respectively.

3.2 Rat study
3.2.1 SO2 and THb baselines

The tissue physiological parameters were extracted from the FDPM measurements at each time point for each
animal using Eqs. (14)–(16). Figure 5 shows boxplots of the baseline SO2 and THb obtained during carbogen
inhalation (8 animals) and forced CH (10 + 4 animals) studies. No significant difference in the baseline THb and
SO2 was found across all the three animal groups indicating that all the animals used for the study had similar
baselines in their physiology prior to hyperoxic or hypoxia gas breathing. Slightly raising the O2 concentration
from 21% to 30% didn’t significantly change the measured tissue oxygenation showing that the tissue SO2 isn’t
very sensitive to a small increase in O2 from room air.

Figure 5 Boxplots of baseline (a) SO2 and (b) THb for tumors and controls in the carbogen gas and forced CH
studies.

3.2.2 Carbogen inhalation

The physiological responses of a typical rat tumor (Rat #5) to carbogen gas inhalation measured with the sidefiring probe are presented in Figure 6. The tumor SO2 fluctuation was within 4% during the baseline. The mean
SO2 jumped from 58% to 71.5% upon carbogen gas breathing, but did not fully return to the baseline within 20
minutes after being switched back to room air. The fluctuation in THb during the baseline was less than 3 μM.
The mean THb dropped from 92.5 to 88.7 μM upon carbogen gas breathing and returned to the baseline within
20 minutes after being switched back to room air. While similar trend for SO2 has been observed, a slow
increase in THb has been recorded in other rats in this group.

Figure 6 (a) SO2 and (b) THb measured from Rat #5 in pre-, during and post carbogen inhalation.

Figure 7 shows the boxplots of changes in SO2 and THb from the first baseline datapoint (t = 0 minute) for all 8
rats. Significant increase in SO2 from base-line (p = 3.4e-5) was observed during carbogen inhalation. There was
also a significant difference in SO2 between the baseline and recovery phase (p = 0.01) indicating that SO2 did
not fully return to the base-line during the 20 minutes recovery period. Although there was a small increase in
the THb, there was no significant change between the hyperoxia and recovery phases from the baseline (p =
0.74 and 0.12, respectively).

Figure 7 Boxplots of changes in (a) SO2 and (b) THb from the first baseline datapoint (t = 0 minute) for all 8 rats
in the carbogen inhalation study.

3.2.3 Forced CH

The physiological responses of a typical rat tumor (Rat #10) and a normal control (Rat #16) to forced cyclic
hypoxia measured with both the side-firing probe and mouse oximeter are shown in Figure 8. The THb for both
the tumor and control (Figure 8(a) and (c)) showed a slow increase with some fluctuations through the 50minute study period, while both the tissue oxygenation measured by the side-firing probe (Figure 8(b)) and
arterial blood oxygenation recorded by the MouseOx (Figure 8(d)) followed the cycles of the oxygen supply
pattern as shown in Figure 3(b). It is worth noting that the tissue SO2 is an average over the tissue volume under
the side-firing probe which is roughly about 1 cm in diameter and thus is lower than the arterial blood saturation
measured with the MouseOx. This is to be expected as there are longitudinal gradients in oxygen when going
from the heart to the peripheral arterial circulation as reported by Dewhirst [17]. We also noticed that the
response in the tissue oxygenation has a slight delay from that of the arterial blood saturation.

Figure 8 Typical THb and SO2 measured in the forced CH study from a rat tumor (Rat #10, (a) and (b)) and a
normal control (Rat #16, (c) and (d)).
Figure 9 shows the boxplots of changes in THb and SO2 (from t = 0 minute) for normal tissue during normoxia
(NN, 4 rats), normal tissue during hypoxia (NH, 4 rats), tumor tissue during normoxia (TN, 10 rats) and tumor
tissue during hypoxia (TH, 10 rats). The normoxia (NN and TN) includes all the data points collected during 30%
O2 breathing and the hypoxia (NH and TH) includes all data points measured during 12% O2 breathing.
Significant differences in ΔSO2 were found between normoxia and hypoxia for both normal (p = 0.024) and
tumors (p = 4.2–6) (Figure 9(a)). ΔTHb was significantly higher only for tumors during hypoxia (Figure 9(b)).

Figure 9 Boxplots of changes (from the 1st data point) in (a) SO2 and (b) THb for normal tissue during normoxia
(NN), normal tissue during hypoxia (NH), tumor tissue during normoxia (TN) and tumor tissue during hypoxia
(TH). The normoxia (NN and TN) includes all the data points collected under 30% O2 supply and the hypoxia (NH
and TH) includes all data points measured under 12% O2 supply.

3.2.4 Natural CH

A total of 4 rats in Group 3 were used to evaluate the capability of the side-firing probe in capturing natural CH
in the tumor. In one of the 2 rats in Group 3A, the probe wasn’t in good contact with the tumor surface because
the tumor was too stiff. Figure 10(a) shows the tissue oxygenation measured from the other rat in Group 3A on
both the right flank muscles and a tumor at a size of 2 cm × 1.7 cm on the left flank. In the normal flank, small
fluctuations at a frequency around 2–3 minutes per cycle with a slow increase in the mean tissue SO2 were
recorded. In the opposite flank bearing the FaDu tumor, large fluctuations on top of the small cycles were
observed. Similar trend was observed in the concurrently measured THb for both the flank muscles (data not
shown in the figures) and and tumor (Figure 10(b). The tumor THb is plotted with SO2 in Figure 10(b), indicating
that tumor oxygenation followed the same trend as total hemoglobin content.

Figure 10 Results measured from the rat in Group 3A: (a) Tissue oxygenation measured from the right flank
muscles and at a tumor size of 2 cm × 1.7 cm on the left flank; and (b) tumor total hemoglobin concentration
and oxygenation measured concurrently.
In Group 3B, one of the two tumors grew on the edge of the left flank making it difficult to attach the probe
directly on top of the tumor. Figure 11 shows the tissue SO2 and THb measured from the left flank of the other
rat in Group 3B before tumor cells were injected and at three different tumor sizes: invisible (under the skin), 5
mm × 6 mm, and 17 mm × 13 mm. For both tissue parameters, small, but fast fluctuations have been recorded
for the muscles (with relatively large slow drifts) and tumor at all sizes, but large and fast amplitude fluctuations
were seen only in the 5 mm tumor during the last 50 minutes of the 150 minute measurement period.

Figure 11 Tissue SO2 (a) and THb (b) measured from the rat in Group 3B before tumor cells were injected and at
three different tumor sizes.

4. Discussion
Many studies have shown that tumor angiogenesis and hypoxia, particularly CH, can significantly influence the
efficacy of radiotherapy and chemotherapy as well as the behavior of surviving cancer cells. Being able to
quantify tumor physiological parameters noninvasively and longitudinally has significant value in studying tumor
natural variations in the hypoxic profile of the tumor. We have developed a side-firing fiber optic sensor based
on frequency-domain photon migration technology that can be used to quantify tissue optical and physiological
parameters in vivo. The flat design of the side-firing probe makes it easily attachable to any flat surface for
longitudinal measurements. We have also developed LabVIEW software that integrates data acquisition and the
user interface with a semi-infinite diffusion approximation model in Matlab, which makes it possible to analyze
the data and display the physiological parameters in real-time.
The system was validated in a phantom study with 15 tissue-simulating phantoms constructed from Intralipid as
scatterer and diluted Indian ink as absorber and the results indicated that the technology can quantify tissue
absorption and scattering coefficients with good accuracy. We have compared a frequency-dependent phase
offset factor 𝑍𝑍(𝜆𝜆, 𝑓𝑓) with a frequency-independent factor 𝑍𝑍(𝜆𝜆) for phase calibration and found that the former
significantly improved the fits between the experimental and modeled phase shift. We also found that a
weighting factor α between 0.8–0.9 (vary from phantom to phantom) during the non-linear least square fit
slightly improved the fits comparing to equal weight that was used in our previous studies [28] as well as by
other groups. The need for larger weight on the amplitude is likely due to the fact that the relative amplitude
attenuation is always below 1.0 while the phase shift in degree is often on the order of a few degrees. The

signal-to-noise ratio (SNR) in the amplitude and phase signals could also have played a role in determining the
optimal weighting factor 𝛼𝛼.

The performance of the FDPM system and side-firing sensor was also evaluated for quantification of tissue
hemoglobin concentration and oxygenation in pre-clinical studies with 26 athymic nude rats during hyperoxia,
forced CH and natural CH.
In all experiments, a small but continuous increase in THb was observed as shown in Figures 7(b), 8(a),
8(c), 9(b), 10(b) and 11(b). There are controversial arguments in the literature on the effects of carbogen gases
on tumor THb. There are many investigators who believe that carbogen is vasodilatory – that it could increase
blood volume. However, T.J. Dunn et al. found that it was vasoconstrictive [33]. During forced hypoxia, both
normal tissue rats and tumors showed raised THb concentration from normoxia as shown in Figure 9b. This is
likely due to the increased oxygen deficiency in the animals that has triggered an increase in the blood flow.
Probe pressure could also have played a role in modifying the THb concentration by pushing away some of the
blood from the areas under the probe when the probe was first taped on the rat skin. This probe pressure
released slowly during the course of the experiment allowing some blood to return to the area.
Significant increase in SO2 upon carbogen inhalation and decrease upon forced hypoxic gas breathing were
recorded. Although the increase in tissue SO2 was quick in both experiments, it took the tumor SO2 more than
20 minutes to fully recover to the baseline in the carbogen experiment (Figure 7(a)), while both the tumor and
normal tissue SO2 in the forced hypoxia study returned to the baseline (or 30% O2 ) within 1–2 minutes (Figure
8(b) and (d)). In another words, the animals can deliver oxygen to hypoxic regions much sooner than they can
consume the extra oxygen in the region while there is adequate supply in the blood vessels. The trend of tissue
oxygenation for both tumor and normal tissues in the forced CH procedures agree well with that measured with
the mouse pulse oximeter from the rat feet, though there was a slightly longer response time in the tissue
oxygenation. This time delay is due to the time needed for the oxygen in the arterial blood vessels to reach the
microvasculatures in the tumor tissue. The tumors also showed a larger oxygenation change under reduced
oxygen supply (from 21% down to 12%) than the normal controls (Figure 9(a)) which can be explained by the
fact that normal tissue can regulate the imbalance between oxygen supply and needs more efficiently than a rat
with a tumor.
In the two animals breathing room air small fluctuations (less than 5%) in SO2 were observed with a 2–3 minute
period in both flank muscles and tumors (Figures 10(a) and and11).11). Strong fluctuations (over 10%) at a
similar frequency in SO2 were also observed in tumors. Both the patterns and frequencies of the natural CH are
very similar to what Braun measured in R3230Ac rat tumors and muscles, using invasive polarographic
electrodes [34]. By plotting the tumor total hemoglobin content with the SO2 measured concurrently from the
same tumor (Figure 10(b)), it can be seen that the two parameters followed nearly the same trend. This finding
supports the conclusions that natural CH can be attributed to fluctuations in red blood cell flux through a vessel
[2, 8, 11, 12]. It was also found that natural CH did not occur in all tumor stages as indicated in Figure 11. More
systematic investigation is required to fully understand the characteristics of natural CH and its relationship with
tumor growth, metastasis and response to therapy.
Finally, the magnitudes of fluctuations in SO2 and THb for the tumor in Figure 10 (about 20% and 100 μM
roughly) are much larger than that for the tumor in Figure 11 (7% and 20 μM). This difference in SO2 and THb
fluctuations as well as their baseline is attributed to the large heterogeneity both between and within tumor
types. Even though Fourier transform analysis in other studies revealed similar kinetics overall, there is still a lot
of heterogeneity, even for the same tumor type and tumor size [34–36]. This is likely due to the fact that the
underlying biology that causes cycling hypoxia is complex. We believe that it is a reflection of several
phenomena, any one of which might be dominant at any time of observation: 1) Arteriolar vasomotion, 2)

rheological changes in hypoxic vasculature that affects how red cells are distributed at bifurcations and 3)
vascular remodeling [35–37].

5. Conclusion
The studies reported in this paper demonstrated the ability of the FDPM and side-firing sensor technology to
quantify tissue physiological properties noninvasively and in real-time. Because the flat probe can be easily and
reliably attached to a tumor surface, it is particularly suitable for monitoring tumor physiological changes at
multiple time points per day for a period of several days or even weeks. Although a head and neck tumor model
was used in this study for performance evaluation, the technology is readily applicable to the diagnostics and
therapeutics for other cancer types.
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